Navigation Links
REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart

ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that REPEL-CV Bioresorbable Adhesion Barrier has received the endorsement of Kids With Heart National Association for Children's Heart Disorders, Inc. Michelle L. Rintamaki, Director of Kids With Heart, stated, "We want to inform parents of children with congenital heart defects about this new surgical device that reduces the risks associated with adhesions during repeat open-heart surgical procedures."

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the patient risk, length and cost of the surgical procedure.


REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions. It was recently approved by the US Food and Drug Administration for use in pediatric patients who undergo staged open-heart surgical procedures.

About Kids With Heart NACHD, Inc.

The organization was formed in 1985 with the main mission of providing support, information, and education to the families of children living with congenital heart defects and to promote public awareness of the issues that these families live with on a day to day basis. It is a 501(c)3 organization entirely supported by volunteers.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technologies.

Statements in this press release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008, for a description of these, as well as other, risks and uncertainties.

SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
3. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
4. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
5. Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study
6. Nanoengineered barrier invented to protect plastic electronics from water degradation
7. Barrier Therapeutics to Merge Into Stiefel Laboratories
8. Study Reveals Greatest Barrier to Green Supply Chain Initiatives
9. Physicists tweak quantum force, reducing barrier to tiny devices
10. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
11. Breaking barriers with nanoscale lasers
Post Your Comments:
(Date:10/12/2017)... NY (PRWEB) , ... October 12, 2017 , ... ... of Sciences today announced the three Winners and six Finalists of the 2017 ... given annually by the Blavatnik Family Foundation and administered by the New York ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):